In KIRC, BRDT reduces the expression of c-MYC in RCC by regulating EIF4EBP1 and further enhances BRDT-targeted treatment RCC by regulating EIF4EBP1 or c-MYC (Wan et al., 2020). This evidence concerns the gene MYC and renal cell carcinoma.